Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature

  • 1Email author,
  • 1, 2 and
  • 3
BMC Psychiatry201515:270

https://doi.org/10.1186/s12888-015-0657-9

©  Barkla et al. 2015

  • Received: 22 June 2015
  • Accepted: 19 October 2015
  • Published:
Open Peer Review reports

Abstract

Background

Among young people up to 18 years of age, approximately 5 % have attention deficit hyperactivity disorder (ADHD), many of whom have symptoms persisting into adulthood. ADHD is associated with increased risk of co-morbid psychiatric disorders, including substance misuse. Many will be prescribed medication, namely methylphenidate, atomoxetine, dexamphetamine and lisdexamfetamine. If so, it is important to know if interactions exist and if they are potentially toxic.

Methods

Three databases (Medline, EMBASE and PsychINFO) from a 22 year period (1992 – June 2014) were searched systematically. Key search terms included alcohol, substance related disorders, methylphenidate, atomoxetine, dexamphetamine, lisdexamfetamine, and death, which identified 493 citations (344 after removal of duplicates). The eligibility of each study was assessed jointly by two investigators, leaving 20 relevant articles.

Results

We identified only a minimal increase in side-effects when ADHD medication (therapeutic doses) was taken with alcohol. None of the reviewed studies showed severe sequelae among those who had overdosed on ADHD medication and other coingestants, including alcohol.

Conclusions

The numbers across all the papers studied remain too low to exclude uncommon effects. Also, studies of combined effects with novel psychoactive substances have not yet appeared in the literature. Nevertheless, no serious sequelae were identified from combining ADHD medication with alcohol/illicit substances from the pre-novel psychoactive substance era.

Keywords

  • Attention deficit hyperactivity disorder
  • Systematic review
  • Alcohol
  • Illicit drugs
  • Medication

Background

Among young people up to 18 years of age, approximately 5 % world-wide are said to have attention deficit hyperactivity disorder (ADHD), a neurodevelopmental syndrome of impulsiveness, inattention, and overactivity that can result in long-term educational and social disadvantage [1, 2]. Symptoms persist into adulthood for a significant minority [3]. Co-morbid substance use disorders (SUD) involving alcohol and cannabis misuse but also stimulants, depressants, hallucinogens and now novel psychoactive substances (NPS) or ‘legal highs’ emerge in adolescence [4]. Young people with ADHD are significantly more likely to develop SUDs than those without ADHD [5].

Many people with ADHD are prescribed medication for their symptoms, particularly stimulants, (often methylphenidate and dexamphetamine) and atomoxetine (NICE 2006). If an individual is suspected of misusing substances, it is crucial to understand if it safe also to prescribe medication. We contacted the manufacturers who recommended that stimulants and atomoxetine not be coingested with alcohol or illicit substances. They had no specific information on potential interactions.

There is limited empirical evidence to guide whether it is advised to treat ADHD before, simultaneously, or only after remission of SUDs [6, 7]. Current guidelines suggest that cannabis use may not be a contraindication to pharmacological treatment but due to shared neurochemical mechanisms, and while not explicitly mentioned, certain novel psychoactive substances (NPAs), ‘cocaine is likely to be a real hazard’ [8]. In the absence of such information, faced with adolescents misusing substances the tendency is for clinicians to avoid prescribing. As adolescents with untreated compared to treated ADHD may have poorer long-term outcomes, this may leave the most vulnerable without adequate intervention [9].

Methylphenidate and dexamphetamine are sympathomimetic agents thought to act both in the central nervous system (CNS) and peripherally by enhancing dopaminergic and noradrenergic transmission through blockade of relevant transporters [10]. There is theoretical potential and some animal evidence for additive effects between prescribed and non-prescribed sympathomimetic agents [11, 12] potentially resulting in a toxic sympathomimetic syndrome with prominent cardiac and neurological effects [10, 12]. Such a syndrome may underly so-called ‘excited delirium’; agitation, paranoia, hyperthermia and muscle breakdown, symptoms similar to neuroleptic malignant syndrome [13]. However, there is also evidence that different stimulants may compete for receptor binding sites limiting the potential for additive effects [14].

Atomoxetine is a selective noradrenaline reuptake inhibitor metabolised by the hepatic oxidase system [15]. It has a chemical structure that resembles the SSRI fluoxetine, that has been implicated in the emergence of mania or the serotonin syndrome, comprised of mental, autonomic and neurological effects [16]. This suggests that toxic or tolerability effects could arise in alcohol misusing individuals [17], through additive effects with stimulants or with NPS that impact serotonin receptors.

Methods

We systematically searched three databases (Medline, EMBASE and PsychINFO) from the past 22-years (1992 – June 2014) using PRISMA guidelines [18]. Only those articles that had abstracts available in the English language were included. We used the key search terms alcohol, substance related disorders, death, and combined these with methylphenidate, atomoxetine, dexamphetamine and lisdexamfetamine in turn.

Titles and abstracts of all articles found were screened by XB and PM. Full text articles were screened by XB and PM. The references of all full text articles included were also hand searched to identify any other potentially relevant articles. Study quality was assessed using the relevant tools from Critical Appraisal Skills Program (CASP) or the STROBE document as appropriate to the study type [19].

We included articles which mentioned the coingestion of ADHD medication (methylphenidate, dexamphetamine, lisdexamfetamine and atomoxetine) with another substance including alcohol, publications relating to animal models, and, due to the paucity of data regarding adolescents, all age groups. Also, to clarify mechanisms that might underlie toxicity, we included certain articles covering the physiological effects of ADHD medication alone. We excluded articles relating to the abuse of ADHD medication alone, case reports, articles relating to exposure of illicit drugs or alcohol in utero, foetal alcohol syndrome, and to cigarette smokers only.

Our main outcome was to identify any potential effects (whether positive or negative) on an individual should they combine their ADHD medication with alcohol or an illicit substance. We acknowledge the dangers of diversion of stimulant medication in the substance misuse population; however our study did not focus on this element.

Results

The search strategy identified 493 citations (344 after removal of duplicates), of which 59 were potentially relevant. We also obtained 6 other articles from hand searching the references, providing 65 articles (Fig. 1). Twenty articles met inclusion criteria. In relation to bias, six of the included studies were found to have a low risk of bias [20–25], four a high risk [26–29] and 10 an unsure risk of bias [17, 30–38].
Fig. 1
Fig. 1

Flow chart of systematic review and study selection

Discussion

Methylphenidate and alcohol

There was one animal study of methylphenidate and alcohol [31] and four of the combination in humans [28, 29, 34, 36]. The animal study reported that methylphenidate reduced the consumption of ethanol by mice and when simultaneously injected, ethanol and methylphenidate interact to increase locomotor stimulation and ataxia [31].

One human study was laboratory based and suggested that when delivered experimentally by mouth, the combination was well tolerated without serious adverse effects [34]. Two studies of users reported that alcohol ingestion often preceded that of methylphenidate and, interspersed with methylphenidate, continued over repeated administrations [28, 29]. Participants reported consuming significantly more alcohol when used in conjunction with methylphenidate relative to when they used alcohol alone. Combined methylphenidate-alcohol use was described as producing euphoria, energy and a diminished sense of drunkenness. Some likened the experience to using alcohol with cocaine. A final human study combined data from randomized controlled trials of methylphenidate treatment of ADHD among substance users. This reported that adolescents with higher baseline use of ethanol were more likely to have gastrointestinal symptoms (not further defined) relative to placebo [36]. However there was no significant difference in serious adverse events between treatment groups. They found no increase in the diversion of methylphenidate in the substance misuse versus the placebo group.

Methylphenidate with other drugs

Two trials of methylphenidate among users of other amphetamine and cocaine [35, 39] and one experimental toxicology study reported no serious adverse effects [36]. However, cocaine users taking methylphenidate reported loss of the positive subjective effects of cocaine and more sadness, euphoria and insomnia. A meta-regression [25] and an RCT [40] reported that as a treatment for ADHD, methylphenidate was ineffective in the presence of SUD.

Two accident and emergency toxicology studies reported no additional toxicity when methylphenidate was combined with other agents [27, 32]. A randomized cross-over placebo controlled trial reported that, in the main, the combination of methylphenidate produced MDMA type effects but increased blood pressure to a greater degree than either alone [14].

Dexamfetamine

Two studies examined combinations of dexamfetamine with alcohol [22, 38]. As with methylphenidate, participants reported that using dexamphetamine made it possible to ‘drink like a trooper’ while socializing for longer, with less perceived drunkenness or loss of control than with alcohol alone.

Atomoxetine

Two studies explored combinations of atomoxetine and alcohol [17, 21]. Nausea was more likely in heavy drinkers taking atomoxetine, however there were no other differences in treatment emergent side effects.

Conclusions

As diagnoses of ADHD have increased among young people of substance using age, the problem of prescribing for substance users with ADHD has become a common dilemma [31]. This review explores current available information concerning risks of toxicity attached to pharmacological treatment of ADHD in the context of substance misuse.

On the basis of experimental studies, and studies of alcohol dependent individuals, when methylphenidate, dexamphetamine or atomoxetine are ingested orally with alcohol, acute severe side-effects appear uncommon. However, as co-ingestion of stimulants such as methylphenidate or amphetamine with alcohol may enable more ‘late night partying’ and high levels of alcohol consumption, there is enhanced risk of more chronic harm from alcohol toxic effects [29, 31]. We did not identify serious adverse side-effects in those with poly-drug misuse using ADHD medication, even in overdose.

Despite the theoretical possibility of serotonergic, hyperdopaminergic or other hyper stimulated states, on the basis of limited evidence, apart from one study suggesting hypertension following a combination of methylphenidate and MDMA, ADHD medication does not normally add to toxicity of alcohol or illicit substances from the pre-novel psychoactive substance (NPS) era.

Limitations include the relatively small numbers in the studies cited. In part, this may reflect a fundamental problem with the science highlighted by Bauman [41]; banning psychoactive agents seriously impedes research into the effects of substances in widespread use alone and in combination by large numbers of young people. In addition, there is no data concerning combinations of cannabis and ADHD medications. However, as cannabis is ubiquitous in the substance using community, it is likely that many adolescents prescribed medications are also using cannabis apparently without acute mishap. However, we lack data concerning any longer term problems with this practice. The effect of combining ADHD medication and NPS is unknown and the numbers in published studies are too few to exclude unusual reactions. ADHD medication appears less effective or even ineffective among those with SUD and if nevertheless prescribed, its use, efficacy and combination with other substances should be closely monitored in an appropriately cautioned consumer.

With appropriate caution, including explanations of the limits of the science, it appears that a blanket contraindication is not justified when considering treatment of ADHD in selected substance users.

Declarations

Acknowledgements

We would like to thank the Northumberland, Tyne and Wear NHS Foundation Trust library staff for support in accessing articles. No funding was received for any author involved in this review.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Children and Young People’s Service, Villa 9, Northgate Hospital, Morpeth, Northumberland, UK
(2)
Institute of Health & Society, Newcastle University, Newcastle, UK
(3)
School of Health & Social Care, University of Teesside Middlesbrough, Middlesbrough, UK

References

  1. Erskine HE, Ferrari AJ, Nelson P, Polanczyk GV, Flaxman AD, Vos T, et al. Epidemiological modelling of attention-deficit/hyperactivity disorder and conduct disorder for the Global Burden of Disease Study 2010. J Child Psychol Psychiatry. 2013;54(12):1263–74.View ArticlePubMedGoogle Scholar
  2. Sonuga-Barke EJ. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry. 2005;57(11):1231–8.View ArticlePubMedGoogle Scholar
  3. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.View ArticlePubMedGoogle Scholar
  4. Biederman J, Petty CR, Wilens TE, Fraire MG, Purcell CA, Mick E, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry. 2008;165(1):107–15.View ArticlePubMedGoogle Scholar
  5. Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328–41.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Riggs P, Levin F, Green AI, Vocci F. Comorbid psychiatric and substance abuse disorders: recent treatment research. Subst Abus. 2008;29(3):51–63.View ArticlePubMedGoogle Scholar
  7. Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011;50(9):903–14.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17–37.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Spiller HA, Hays HL, Aleguas Jr A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs. 2013;27(7):531–43.View ArticlePubMedGoogle Scholar
  11. Calipari ES, Ferris MJ, Salahpour A, Caron MG, Jones SR. Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun. 2013;4:2720.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Cleary L, Buber R, Docherty JR. Effects of amphetamine derivatives and cathinone on noradrenaline-evoked contractions of rat right ventricle. Eur J Pharmacol. 2002;451(3):303–8.View ArticlePubMedGoogle Scholar
  13. Takeuchi A, Ahern TL, Henderson SO. Excited delirium. West J Emerg Med. 2011;12(1):77–83.PubMed CentralPubMedGoogle Scholar
  14. Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol. 2014;17(3):371–81.View ArticlePubMedGoogle Scholar
  15. Castellanos FX, Meyer E. Toward systems neuroscience of shared and distinct neural effects of medications used to treat attention-deficit/hyperactivity disorder. Biol Psychiatry. 2013;74(8):560–2.View ArticlePubMedGoogle Scholar
  16. Birmes P, Coppin D, Schmitt L. Lauque D. Serotonin Syndrome. 2003;168(11):1439–42.Google Scholar
  17. Adler L, Wilens T, Zhang S, Durell T, Walker D, Schuh L, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict. 2009;18(5):393–401.View ArticlePubMedGoogle Scholar
  18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339:b2700.View ArticleGoogle Scholar
  19. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (Clinical research ed). 2007;335(7624):806–8.View ArticleGoogle Scholar
  20. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1–2):145–54.View ArticlePubMedGoogle Scholar
  21. Wilens TE, Adler LA, Tanaka Y, Xiao F, D’Souza DN, Gutkin SW, et al. Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Curr Med Res Opin. 2011;27(12):2309–20.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Green R, Moore D. ‘Kiddie drugs’ and controlled pleasure: recreational use of dexamphetamine in a social network of young Australians. Int J Drug Policy. 2009;20(5):402–8.View ArticlePubMedGoogle Scholar
  23. Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 2013;27(1):15–30.View ArticlePubMedGoogle Scholar
  24. Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. PLoS One. 2013;8(1):e52991.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011;25(2):157–69.View ArticlePubMedGoogle Scholar
  26. Perez de los Cobos J, Sinol N, Perez V, Trujols J. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol. 2014;77(2):337–56.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Hill SL, El-Khayat RH, Sandilands EA, Thomas SH. Electrocardiographic effects of methylphenidate overdose. Clinical Toxicol (Philadelphia, Pa). 2010;48(4):342–6.View ArticleGoogle Scholar
  28. Barrett SP, Darredeau C, Pihl RO. Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacol. 2006;21(4):255–63.View ArticleGoogle Scholar
  29. Barrett SP, Pihl RO. Oral methylphenidate-alcohol co-abuse. J Clin Psychopharmacol. 2002;22(6):633–4.View ArticlePubMedGoogle Scholar
  30. Griffin 3rd WC, McGovern RW, Bell GH, Randall PK, Middaugh LD, Patrick KS. Interactive effects of methylphenidate and alcohol on discrimination, conditioned place preference and motor coordination in C57BL/6J mice. Psychopharmacology. 2013;225(3):613–25.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Griffin 3rd WC, Novak AJ, Middaugh LD, Patrick KS. The interactive effects of methylphenidate and ethanol on ethanol consumption and locomotor activity in mice. Pharmacol Biochem Behav. 2010;95(3):267–72.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Bruggisser M, Bodmer M, Liechti ME. Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly. 2011;141:w13267.PubMedGoogle Scholar
  33. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089–96.View ArticlePubMedGoogle Scholar
  34. Koehm M, Kauert GF, Toennes SW. Influence of ethanol on the pharmacokinetics of methylphenidate’s metabolites ritalinic acid and ethylphenidate. Arzneimittelforschung. 2010;60(5):238–44.PubMedGoogle Scholar
  35. Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend. 2010;108(1–2):130–3.View ArticlePubMedGoogle Scholar
  36. Winhusen TM, Lewis DF, Riggs PD, Davies RD, Adler LA, Sonne S, et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(5):455–63.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33(10):821–42.View ArticlePubMedGoogle Scholar
  38. Simons R, Martens M, Ramaekers J, Krul A, Klopping-Ketelaars I, Skopp G. Effects of dexamphetamine with and without alcohol on simulated driving. Psychopharmacology. 2012;222(3):391–9.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10(3):286–94.View ArticlePubMedGoogle Scholar
  40. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006;81(2):137–48.View ArticlePubMedGoogle Scholar
  41. Baumann MH. Awash in a sea of ‘bath salts’: implications for biomedical research and public health. Addiction (Abingdon, England). 2014;109(10):1577–9.View ArticleGoogle Scholar

Copyright

© Barkla et al. 2015

Advertisement

BMC Psychiatry

ISSN: 1471-244X

Contact us